What makes you say they'll need a CR? They tightened the shares recently. Seems unlikely they'll reverse that move with a CR.
I had a re-read of their recent announcement of the partnership with ANOVA. They're expecting commercialisation in Australia by the first quarter of 2019, through their partnership with Monash. They'll begin clinical testing with Monash in early 2019 first quarter. The late 2019 quarter is clinical testing and commerialisation in the EU; however they'll still be able to conduct test with the Felix to see if its functional as MEM claims. Fertilisation wont be until late 2019 with EU testing.
By mid next year, we'll have completed clinical testing at Monash; as in actual fertilisation for real couples. We wont even need to wait until end of 2019 for ANOVA to begin clinical testing because we'll have seen the results already. I'm curious to see how much they'll charge for the Felix console, and how much for each cartridge. Current sperm separation techniques require 1-2 tries minimum and is valued at $10k a try (correct me if Im wrong). These guys are going to fkn blow up after successful clinical trials.
It sounds like I'm upramping, but I have to agree with Kenjikool. By mid next year I think I'd be laughing about today, wishing I had an extra 100k shares.
